Public Market Listing
Live quotes, historical charts, and market capitalization for Shenzhen Salubris Pharmaceuticals are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(7 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule | Chronic Kidney Disease | |
| Phase 3 | PCSK9Monoclonal antibody | Atherosclerotic Cardiovascular Disease | |
| Phase 3 | Endothelin receptor type A (ETA)Small molecule | HypertensionChronic Kidney Disease | |
| Phase 2 | HER3 × ErbB4Biologic (subtype unspecified) | Heart Failure | |
| Phase 2 | Apolipoprotein(a) [apo(a)] / apo(a)-apoB100 interactionSmall molecule | Atherosclerotic Cardiovascular Disease | |
| Phase 2 | Aldosterone synthase (CYP11B2)Small molecule | HypertensionChronic Kidney Disease | |
| Phase 2 | GLP-1 receptorSmall molecule | Type 2 Diabetes |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
2027 (4)
March 2027 (1)
April 2027 (1)
October 2027 (1)
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (4)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $177M | $19M | $157M | — | report ↗ |
View 3 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $453M | $51M | $139M | — | report ↗ |
| 2025-H1 | $294M | $32M | $120M | — | report ↗ |
| 2025-Q1 | $146M | $15M | $196M | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $606M | $75M | $138M | — | report ↗ |
Shenzhen Salubris Pharmaceuticals reported revenue of $605.98M for fiscal 2025, up 8.5% YoY, with R&D spend of $75.09M, up 28.1% YoY. Cash and equivalents stood at $138.33M. Net income or loss and quarterly net burn were not disclosed, and no analyst consensus comparison was provided.
The company disclosed that its innovative siRNA drug SAL0195 received clinical trial approval for a lipoprotein-related indication, and that its sacubitril/alisartan/amlodipine tablet had a marketing application accepted for review. No forward-looking guidance was stated in the material.